Lead Sponsor

University of Wisconsin, Madison

Age

18 - 40 years

Sex

MALE

Healthy Volunteers

No

•1. Cases: Men aged 18 to 40 years with a confirmed diagnosis of UC or CD based on endoscopy, pathology, and/or radiology AND who regularly take MTX (per oral, subcutaneous, or intramuscular) either as monotherapy or in combination with mesalamine (any except sulfasalazine), corticosteroids, anti-TNF agents, or anti-adhesion molecules for at least one month specifically for the treatment of IBD. Controls: Men aged 18 to 40 years with a confirmed diagnosis of UC or CD based on endoscopy, pathology, and/or radiology AND who do not take MTX (per oral, subcutaneous, or intramuscular) either as monotherapy or in combination with other IBD-specific drugs.
•2. Individual able and willing to consent to donate their sperm to research.

•1. Men with previously documented problems with male reproductive health such as known hypothalamic-pituitary disorders (e.g. pituitary macroadenomas, pituitary infarction), primary hypogonadism (e.g. cryptorchidism, Klinefelter's syndrome), or disorders of sperm transport (e.g. erectile dysfunction, history of vasectomy)
•2. Current use of alkylating agents, ketoconazole, sulfalsalazine, H2-receptor antagonists or spironolactone
•3. Men who have undergone ileal pouch anal anastomosis within 3 months of study entry

Related studies

NCT07245394 · Inflammatory Bowel Disease (IBD), Crohn Disease (CD), and more

NCT07385131 · Inflammatory Bowel Disease (IBD), CD - Crohn's Disease, and more

NCT06502873 · Inflammatory Bowel Disease (IBD)

NCT04806620 · Post-Acute COVID-19 Syndrome, ME/CFS, and more

NCT07224113 · IBD, Crohn Disease (CD), and more

The Effect of Methotrexate on Sperm Quality in Men With Inflammatory Bowel Disease